DrugPatentWatch Database Preview
Investigational Drug Information for GDC-0152
Email this page to a colleague
What is the drug development status for GDC-0152?
GDC-0152 is an investigational drug.
There have been 183 clinical trials for GDC-0152.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2016.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are sixty-five US patents protecting this investigational drug and one international patent.
Summary for GDC-0152
| US Patents | 65 |
| International Patents | 1,149 |
| US Patent Applications | 136 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 64 |
| Clinical Trial Progress | Phase 3 (2016-12-13) |
| Vendors | 25 |
Recent Clinical Trials for GDC-0152
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | Kazia Therapeutics Limited | Phase 2 |
| Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | Lakshmi Nayak | Phase 2 |
Clinical Trial Summary for GDC-0152
Top disease conditions for GDC-0152
Top clinical trial sponsors for GDC-0152
US Patents for GDC-0152
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GDC-0152 | ⤷ Try it Free | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (Cambridge, MA) | ⤷ Try it Free |
| GDC-0152 | ⤷ Try it Free | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Try it Free |
| GDC-0152 | ⤷ Try it Free | Bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Try it Free |
| GDC-0152 | ⤷ Try it Free | NAMPT and ROCK inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Try it Free |
| GDC-0152 | ⤷ Try it Free | Bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | ⤷ Try it Free |
| GDC-0152 | ⤷ Try it Free | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (La Jolla, CA) SALK INSTITUTE FOR BIOLOGICAL STUDIES (La Jolla, CA) | ⤷ Try it Free |
| GDC-0152 | ⤷ Try it Free | Certain protein kinase inhibitor | CHONGQING FOCHON PHARMACEUTICAL CO., LTD. (Chongqing, CN) SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (Shanghai, CN) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GDC-0152
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GDC-0152 | China | CN108368161 | 2035-09-10 | ⤷ Try it Free |
| GDC-0152 | European Patent Office | EP3347372 | 2035-09-10 | ⤷ Try it Free |
| GDC-0152 | Japan | JP2018528217 | 2035-09-10 | ⤷ Try it Free |
| GDC-0152 | World Intellectual Property Organization (WIPO) | WO2017044633 | 2035-09-10 | ⤷ Try it Free |
| GDC-0152 | Argentina | AR095266 | 2033-03-12 | ⤷ Try it Free |
| GDC-0152 | Australia | AU2014231563 | 2033-03-12 | ⤷ Try it Free |
| GDC-0152 | Australia | AU2018203833 | 2033-03-12 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
